title: Routine treatment of patients with chronic lymphocytic leukaemia by office-based haematologists in Germany-data from the Prospective Tumour Registry Lymphatic Neoplasms.
abstract: Various treatment options exist for patients with chronic lymphocytic leukaemia (CLL). Clinical registries provide insight into routine treatment and identify changes in treatment over time. The Tumour Registry Lymphatic Neoplasms prospectively collects data on the treatment of patients with lymphoid B-cell neoplasm as administered by office-based haematologists in Germany. Data on patient and tumour characteristics, co-morbidities, systemic treatments, and outcome parameters are recorded. Eight hundred and six patients with CLL were recruited between May 2009 and August 2013. At the start of first-line treatment, median age was 71 years, 64% were male, and 44% had a Binet stage C disease. The most frequently used first-line/second-line regimens were bendamustine + rituximab (BR, 56%/55%), fludarabine + cyclophosphamide + rituximab (FCR, 22%/11%), and bendamustine (B, 5%/9%). Chlorambucil was used in only 7% (first-line) and 6% (second-line) of patients. Patients treated with FCR were younger and healthier than patients treated with BR. Overall, 91% of first-line treatments were successful (40% complete response). Real-life patient populations differ considerably from patients treated in randomized controlled trials. BR and FCR dominate the first-line and second-line treatments of CLL by office-based haematologists in Germany. Future analysis will investigate progression-free and overall survival times.
authors.affiliation: Onkologische Gemeinschaftspraxis, Frankfurt am Main, Germany.
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Knauf
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Abenhardt
authors.forename: Steffen
authors.initials: S
authors.lastname: Dörfel
authors.forename: Dirk
authors.initials: D
authors.lastname: Meyer
authors.forename: Renate
authors.initials: R
authors.lastname: Grugel
authors.forename: Michaela
authors.initials: M
authors.lastname: Münz
authors.forename: Holger
authors.initials: H
authors.lastname: Hartmann
authors.forename: Norbert
authors.initials: N
authors.lastname: Marschner
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000069461:Bendamustine Hydrochloride; D002699:Chlorambucil / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D005260:Female; D005858:Germany; D006405:Hematology / Q000379:methods / Q000706:statistics & numerical data; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D008297:Male; D009588:Nitrogen Mustard Compounds / Q000008:administration & dosage; D009819:Office Visits / Q000706:statistics & numerical data; D011241:Prednisone / Q000008:administration & dosage; D011446:Prospective Studies; D012042:Registries / Q000706:statistics & numerical data*; D000069283:Rituximab; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D009588:Nitrogen Mustard Compounds; D002699:Chlorambucil; D000069283:Rituximab; D003520:Cyclophosphamide; D000069461:Bendamustine Hydrochloride; D014740:Vidarabine; C024352:fludarabine; D011241:Prednisone
keywords: Germany/epidemiology; ambulatory care; chronic lymphocytic leukaemia; drug therapy/statistical and numerical data; registries
references.citation: N Engl J Med. 2000 Dec 28;343(26):1910-6
references.pmid: 11136261
references.citation: Blood. 2008 Jun 15;111(12):5446-56
references.pmid: 18216293
references.citation: Cancer. 1977 Aug;40(2):855-64
references.pmid: 890666
references.citation: Lancet. 2007 Jul 21;370(9583):230-239
references.pmid: 17658394
references.citation: Blood. 2009 Oct 15;114(16):3382-91
references.pmid: 19605849
references.citation: Ann Oncol. 2011 Sep;22 Suppl 6:vi50-4
references.pmid: 21908504
references.citation: Br J Haematol. 2012 Oct;159(1):67-77
references.pmid: 22861163
references.citation: J Clin Oncol. 2008 Nov 1;26(31):5094-100
references.pmid: 18711173
references.citation: Blood. 2009 Sep 3;114(10):2044-50
references.pmid: 19553638
references.citation: J Clin Oncol. 2012 Sep 10;30(26):3209-16
references.pmid: 22869884
references.citation: Lancet. 2010 Oct 2;376(9747):1164-74
references.pmid: 20888994
references.citation: Cancer. 1981 Jul 1;48(1):198-206
references.pmid: 7237385
references.citation: J Clin Oncol. 2009 Sep 10;27(26):4378-84
references.pmid: 19652068
references.citation: Blood. 2006 Feb 1;107(3):859-61
references.pmid: 16223776
references.citation: J Chronic Dis. 1987;40(5):373-83
references.pmid: 3558716